Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institutes of Health (NIH) | NIH |
| amfAR, The Foundation for AIDS Research | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
This the propose to use the Multiphase Optimization Strategy Trial (MOST) design to identify an anal HSIL screening algorithm which is most suitable in terms of effectiveness, efficiency, and economy. Specifically, The Investigators will use a factorial design as the main strategy in the MOST, as this allows the evaluation of multiple intervention components that are candidates for ultimate inclusion in the algorithm. The Investigators will then implement the most suitable anal HSIL screening algorithm in the clinic, using the RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) framework to guide its design, implementation, and evaluation. An interrupted time series will be used to compare anal HSIL screening uptake among men who have sex with men clients in the clinic, prior to and after the implementation of the new anal HSIL screening algorithm, and mixed-methods approaches will be used to evaluate components of the RE-AIM framework.
I. PREPARATION PHASE Purpose To lay groundwork for optimization of anal high-grade squamous intraepithelial lesion screening algorithm for MSM, and identify which test and component(s) should be included in the anal HSIL screening algorithm.
II. OPTIMIZATION PHASE Purpose To form an anal high-grade squamous intraepithelial lesion screening algorithm that meets the optimization criteria.
III. EVALUATION PHASE Purpose To establish whether the optimized anal high-grade squamous intraepithelial lesion screening algorithm has a statistically significant effect on service uptake among MSM compared to the standard of care.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1 DARE/CYTOLOGY/HPV/HRA | Other | Participant request physician assessment for Digital anal rectal exam, Anal cytology, Anal HPV test and High resolution anoscopy for every 6 months within 12 months period |
|
| Group 2 DARE/CYTOLOGY/HPV | Other | Participant request physician assessment for Digital anal rectal exam, Anal cytology, Anal HPV test for every 6 months within 12 months period |
|
| Group 3 DARE/CYTOLOGY/HRA | Other | Participant request physician assessment for Digital anal rectal exam, Anal cytology and High resolution anoscopy for every 6 months within 12 months period |
|
| Group 4 DARE/CYTOLOGY | Other | Participant request physician assessment for Digital anal rectal exam, Anal cytology for every 6 months within 12 months period |
|
| Group 5 DARE/HPV/HRA | Other | Participant request physician assessment for Digital anal rectal exam, Anal HPV test and High resolution anoscopy for every 6 months within 12 months period |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| OPTIMIZATION PHASE | Procedure | The goal of the optimization phase of MOST is to identify the most promising combination of experimental components in changing an outcome given a set of environmental constraints. Looking at effectiveness, efficiency, economy, and scalability criteria, we will focus on the proportion of anal HSIL identified (effectiveness), unit cost (efficiency and economy), and accumulating cost to the client over a 12-month period (economy). Meeting these criteria will likely imply scalability. The most appropriate anal HSIL screening algorithm would ideally be one which could - identify anal HSIL in at least 20% of HIV-positive MSM and 10% of HIV-negative MSM at baseline and |
| Measure | Description | Time Frame |
|---|---|---|
| Identify new cases of anal HSIL by Anal HSIL screening algorithm | identify anal HSIL in at least 20% of HIV-positive MSM/TGW and 10% of HIV-negative MSM/TGW within visit schedule. | 18 months |
| Compare anal HSIL screening method to new anal HSIL screening method algorithm | Evaluate anal HSIL screening method uptake among MSM/TGW clients in the clinic compare to the implementation of the new anal HSIL screening method algorithm. | 24 months |
Not provided
Not provided
Inclusion criteria
Clients for MSM and TGW:
Clinic staff:
- Has worked in the study clinic during phase III
Government stakeholders:
- Involved in health policy development in Thailand
Exclusion criteria
Clients for MSM and TGW:
Clinic staff:
- Not willing to participate in the evaluation
Government stakeholders:
- Not willing to participate in the evaluation
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Nittaya Phanuphak, MD,PhD. | Institute of HIV Research and Innovation | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Institute of HIV Research and Innovation | Pathum Wan | Bangkok | 10330 | Thailand |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Group 6 DARE/HPV | Other | Participant request physician assessment for Digital anal rectal exam and Anal HPV test for every 6 months within 12 months period |
|
| Group 7 DARE/HRA | Other | Participant request physician assessment for Digital anal rectal exam and High resolution anoscopy for every 6 months within 12 months period |
|
| Group 8 DARE | Other | Participant request physician assessment for Digital anal rectal exam for every 6 months within 12 months period |
|
| Self-collection CYTOLOGY/HPV | Other | Participant request Self-sampling collection for Anal cytology and Anal HPV test for every 6 months within 12 months period |
|
| Self-collection CYTOLOGY | Other | Participant request Self-sampling collection for Anal cytology for every 6 months within 12 months period |
|
| Self-collection HPV | Other | Participant request Self-sampling collection for Anal HPV test for every 6 months within 12 months period |
|
| Self-collection control group CYTOLOGY/HPV | Other | Participant request Self-sampling collection for Anal cytology and Anal HPV only at month 12 |
|
|